Exhibiting at VIV Asia 2025

Founded in 2005, Qingdao Vland Biotech Inc. is a leading high-tech enterprise specializing in research, development, production, and marketing of biological products in China. With headquarters located in Qingdao, China, the company has steadily grown into a globally recognized biotechnology innovator, focusing on enzyme preparations, microecological agents, and animal health products. The company went public on the Shanghai Stock Exchange in 2018 under the ticker symbol 603739.SH, marking a significant milestone in its growth journey.

Core Business and Offerings

Vland Biotech operates across three major sectors:

• Enzyme Preparations: Vland develops a comprehensive portfolio of enzymes tailored for feed, industrial, food, and biocatalysis applications. These enzymes are engineered for high efficacy, stability, and targeted functionality in specific production environments.

• Microecological Products: The company is a pioneer in microecology, producing probiotics and microbial solutions for livestock, aquaculture, agriculture, food, and environmental sustainability.

• Animal Health Products: Its offerings include biological veterinary products, traditional Chinese veterinary medicines, and veterinary chemical drugs.

Each product segment is backed by robust R&D, with continuous innovation at the core of its value proposition.

Specialisation and Core USP

Vland's strength lies in its vertically integrated R&D ecosystem and proprietary fermentation technologies. With a strong team of over 500 R&D professionals and multiple joint research centers in collaboration with leading universities and international partners, the company has filed over 450 patents and maintains more than 200 valid invention patents.

Its enzyme division is ranked among the top enzyme manufacturers in China, and Vland is widely recognized for its advanced microbial strain breeding, enzyme engineering, and fermentation technology platforms.

Financial Performance

According to Vland’s official financial disclosures for 2022:

• Annual Revenue: RMB 2.57 billion (approx. USD 370 million)
• Net Profit: RMB 279 million (approx. USD 40 million)
• R&D Investment: RMB 238 million, accounting for more than 9% of total revenue
• International Revenue Share: Over 35% of total revenue is derived from overseas markets

The consistent investment in R&D underpins Vland’s strategy of differentiation through innovation.

Shipment and Export Data

Based on trade intelligence from platforms like Volza and ImportYeti:

• Annual Export Shipments: Over 1,800 shipments globally
• Top Export Destinations: United States, Vietnam, India, Indonesia, Brazil
• Major Products Exported: Phytase enzymes, Bacillus subtilis probiotics, and amylase blends
• Export Partners: Vland supplies to global feed and food processing giants, including Cargill and CP Group

This data reinforces Vland's strong international footprint and reliability as a consistent exporter of high-quality biotech products.

Target Market

Vland serves a wide range of industries including:

• Animal feed and nutrition
• Food processing
• Textile and detergent manufacturing
• Agriculture and aquaculture
• Environmental remediation

The company's clientele spans over 60 countries, targeting both B2B customers and integrated solution providers in the biotech and agri-food sectors.

Capabilities

• Manufacturing: 10 state-of-the-art production bases across China with GMP-compliant facilities
• Production Capacity: Annual capacity of over 200,000 tons of enzyme preparations and microbial products
• R&D Infrastructure: 5 research centers and collaborations with institutes in the U.S., Denmark, and China
• Global Supply Chain: Robust logistics and technical support services for cross-border shipping and compliance

Certifications and Compliance

Vland Biotech complies with international standards and holds multiple certifications:

• ISO 9001:2015 (Quality Management)
• FAMI-QS (European Feed Additives and Premixture Quality System)
• GMP Certification (Good Manufacturing Practice for veterinary drugs)
• ISO 22000 and HACCP for food enzyme manufacturing
• REACH and FDA registrations for product compliance in EU and U.S.

These certifications ensure Vland meets the regulatory demands of global markets and consistently delivers safe, high-quality products.

Customer Testimonials

Feedback from global partners highlights the company's consistency and innovation:

"Vland’s feed enzymes have significantly enhanced the digestibility of our poultry diets while reducing feed cost. Their technical team provides reliable support and customization."
— Senior Nutritionist, CP Group

"Their enzymes are among the most stable and effective we’ve used in our textile applications. Very responsive and detail-oriented team."
— Procurement Manager, South Asia Enzymes Pvt Ltd

Major Achievements

• 2018: Successfully listed on the Shanghai Stock Exchange
• 2020: Awarded as one of China’s Top 100 Innovative Enterprises in Biotech
• 2021: Developed a breakthrough phytase enzyme with enhanced thermostability for pelleted feed
• 2023: Launched carbon reduction solutions using microbial fermentation for environmental applications
• Global Partnerships: Strategic collaboration with Novozymes and several Asian biotech universities

Qingdao Vland Biotech Inc. stands as a benchmark in biotech innovation, providing reliable, sustainable, and advanced biological solutions to customers worldwide. Its consistent focus on quality, compliance, and customer-centric R&D continues to make it a preferred partner for industry leaders in food, agriculture, and animal health sectors.